arrow
A

Annette M. Lim

Peter MacCallum Cancer Centre
H指数:20
被引数:2,950

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating CD103+ intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer

评估人乳头状瘤病毒相关口咽癌中,原发肿瘤与淋巴结中CD103+肿瘤内免疫细胞丰度及PD-L1 CPS的差异。

2025-11-210
PRE
A two-phase study investigating the quality of life benefit of additional 0.5% cocaine mouthwash to institutional standard of care mucositis management in head and neck cancer patients undergoing radiotherapy or chemoradiotherapy

一项两阶段研究,探讨在头颈癌接受放疗或放化疗的患者中,额外使用0.5%可卡因漱口水对机构标准护理的黏膜炎管理的生活质量益处。

2025-10-120
OAAI
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
2024-01-115
OAAI
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
2022-10-27142
OA
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

cemiplimab治疗晚期皮肤鳞状细胞癌2期研究的综合分析: 延长随访结果和生活质量分析

2021-08-1960
OAAI
Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
2020-03-013
OAAI
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Cemiplimab在晚期皮肤鳞状细胞癌中的PD-1阻滞

2018-07-26983
OAAI